BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 6, 2014
View Archived Issues
Researchers describe mechanism of action of ProHema
Read More
Acucela completes enrollment in SEATTLE study of emixustat
Read More
Targeting the self-renewal of cancer-initiating cells as a new approach for colorectal cancer
Read More
Janssen Pharmaceutica designs new agents for pain
Read More
Novel SYK inhibitors synthesized at Novartis
Read More
Proteostasis Therapeutics and Cystic Fibrosis Foundation Therapeutics extend collaboration
Read More
Cellectar Biosciences begins phase II imaging trial of [124I]CLR-1404
Read More
Genticel begins phase II trial in women with high-risk HPV
Read More
New milestone reached in Genfit and Sanofi's research collaboration
Read More
Viriom begins new program for chronic hepatitis B
Read More
International Stem Cell reports interim data from stem cell primate study for Parkinson's disease
Read More
Astex receives milestone payment as LEE-011 enters phase III trial
Read More
Eisai and Biogen Idec to collaborate in Alzheimer's disease
Read More
High 12-week sustained virological response rates in PEARL III study
Read More
Vaginal dapivirine effectively protects against HIV challenge
Read More
Novartis reports novel SMN modulators for spinal muscular atrophy
Read More
New KOR-1 antagonists patented by the Scripps Research Institute
Read More
FDA accepts additional Lymphoseek supplemental NDA for review
Read More
Kamada initiates phase II/III trials with intravenous Glassia for the treatment of type 1 diabetes
Read More
FDA issues complete response letter for empagliflozin
Read More
Next-generation sequencing for a rare cancer
Read More
Janssen Biotech to begin phase III study of daratumumab in multiple myeloma
Read More
FDA grants fast track designation to Tekmira's TKM-Ebola
Read More
Regulus Therapeutics initiates phase I study of RG-101
Read More
Agenus selects modulator antibodies to advance into preclinical development
Read More
iCo Therapeutics updates progress of iDEAL study of iCo-007
Read More